Press release
United States AI in Clinical Trials Market to Grow at 14.55% CAGR, Reaching USD 5.06 Billion by 2033, Led by IQVIA, Medidata, and IBM Watson Health | DataM Intelligence
AI in Clinical Trials - generate image
United States: Recent Industry Developments
✅ In October 2025, IQVIA launched an AI-powered platform that reduced patient recruitment time by 40% in Phase III oncology trials.
✅ In October 2025, the FDA approved the first AI-driven clinical trial design platform for adaptive trial protocols.
✅ In October 2025, Medidata Solutions introduced an AI-based monitoring system, cutting trial monitoring costs by 35%.
Japan: Recent Industry Developments
✅ In October 2025, Astellas Pharma implemented AI-powered prediction systems, improving trial success rates by 25%.
✅ In October 2025, Japan's PMDA established a regulatory framework for AI-based clinical trial endpoints.
✅ In October 2025, Sony AI Research partnered to develop generative AI models for synthetic control arms.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/ai-in-clinical-trials-market?jd
Market Trends & Drivers
The AI in Clinical Trials Market is experiencing rapid growth driven by the need to reduce drug development costs, accelerate trial timelines, and improve success rates. Key trends include predictive analytics for patient recruitment, AI-powered risk-based monitoring, and generative AI for synthetic control arms. The increasing complexity of clinical trials, rising R&D costs, and regulatory support for digital innovation are significantly accelerating market adoption.
Competitive Landscape
The market features intense competition among CROs, technology providers, and pharmaceutical companies.
IQVIA Holdings Inc. leads in AI-powered clinical trial solutions with integrated data analytics.
Medidata Solutions dominates in AI-driven clinical trial management and monitoring platforms.
IBM Watson Health provides AI solutions for clinical trial optimization and evidence generation.
NVIDIA Corporation offers AI computing platforms for medical imaging analysis.
Saama Technologies, Inc. specializes in AI-powered clinical data analytics and automation.
Unlearn.AI, Inc. pioneers digital twin technology for clinical trials.
Aetion, Inc. focuses on AI-driven real-world evidence generation.
BioSymetrics Inc. provides machine learning for biomarker discovery.
Concerto HealthAI offers AI solutions for oncology clinical trials.
Trials.AI develops AI-powered platforms for protocol optimization.
Segmentation
By Offering: Software, Services
By Trial Phase: Phase I, Phase II, Phase III
By Indication: Oncology, Central Nervous System (CNS) Disorders, Cardiovascular (CVS) Diseases, Other Indications
By End-User: Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Other End Users
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/ai-in-clinical-trials-market?jd
Regional Analysis:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (Germany, U.K., France, Italy, Spain, Rest of Europe)
⇥ Asia-Pacific (Japan, China, India, South Korea, Australia, Rest of Asia Pacific)
⇥ South America (Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?jd
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us:
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us:
DataM Intelligence is a full-service market research and consulting firm, guiding organizations from initial insight to strategic implementation. We transform proprietary data, emerging trends, and market developments into agile, actionable solutions.
Our robust methodology powers a vast research database featuring 6,300+ syndicated and custom reports across 40+ industries. We have delivered strategic solutions to 200+ companies in 50+ countries, addressing the core research challenges that drive growth for our clients.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States AI in Clinical Trials Market to Grow at 14.55% CAGR, Reaching USD 5.06 Billion by 2033, Led by IQVIA, Medidata, and IBM Watson Health | DataM Intelligence here
News-ID: 4242195 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
United States Hips & Knees Reconstructive: Personalized Implants & 3.6% CAGR By …
Market Size and Forecast:
The Global Hips & Knees Reconstructive Market reached US$ 17.30 billion in 2023 and is expected to reach US$ 22.93 billion by 2031, growing at a CAGR of 3.6% during the forecast period 2024-2031.
The Hips and Knees Reconstructive Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses…
Japan Single-Use Bioprocessing Products Market: Thermo Fisher, Sartorius & Cytiv …
Market Size and Forecast:
Japan Single-Use Bioprocessing Products Market is expected to reach growth at a Significant CAGR during the forecast period 2024-2031
The Japan Single-Use Bioprocessing Products Market Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of…
United States Pharmaceutical Packaging Market to Grow at 9.5% CAGR, Driven by Re …
The global Pharmaceutical Packaging Market is growing at a CAGR of 9.5% during the forecast period 2024-2031, according to DataM Intelligence.
United States: Recent Industry Developments
✅ In October 2025, Amcor PLC launched a new series of recyclable cold-chain packaging solutions for biologic drugs, enhancing sustainability in temperature-sensitive shipments.
✅ In October 2025, West Pharmaceutical Services introduced a novel smart vial system with integrated sensors for real-time temperature and tamper monitoring.
✅…
United States Optical Imaging Market to Grow at 12.4% CAGR, Reaching USD 4.0 bil …
The global Optical Imaging Market reached USD 1.6 billion in 2022 and is projected to reach USD 4.0 billion by 2031, growing at a CAGR of 12.4% during the forecast period 2024-2031, according to DataM Intelligence.
United States: Recent Industry Developments
✅ In October 2025, Canon U.S.A. received FDA clearance for its next-generation optical coherence tomography (OCT) system with AI-enhanced diagnostic capabilities for ophthalmology.
✅ In October 2025, Abbott Laboratories…
More Releases for Trial
Clinical Trial Investigative Site Network Market Clinical Trial Investigative Si …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Clinical Trial Investigative Site Network Market - (By Therapeutic Areas (Oncology, Cardiology, CNS, Pain Management, Endocrine, Others), By Phase (Phase I, Phase II, Phase III, Phase IV), By End-use (Sponsor, CRO)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the Global Clinical Trial Investigative Site Network Market…
Transformative Trends Impacting the Electronic Trial Master File (eTMF) Systems …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Electronic Trial Master File (eTMF) Systems Market Size By 2025?
The market size of the electronic trial master file (eTMF) systems has experienced fast growth over recent years. The market is projected to increase from $1.36 billion in 2024 to $1.55 billion in 2025, with…
Transformative Trends Impacting the Electronic Trial Master File (eTMF) Systems …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Electronic Trial Master File (eTMF) Systems Market Size By 2025?
The market size of the electronic trial master file (eTMF) systems has experienced fast growth over recent years. The market is projected to increase from $1.36 billion in 2024 to $1.55 billion in 2025, with…
Clinical Trial Management System
According to a new market report published by Persistence Market Research “Global Market Study on Clinical Trial Management System: Asia to Witness Highest Growth by 2019” the global clinical trial management system market was valued at USD 844.0 million in 2013 and is expected to grow at a CAGR of 14% from 2014 to 2019, to reach an estimated value of USD 1,848.5 million in 2019.
Request Report TOC @ https://www.persistencemarketresearch.com/methodology/3017
…
Clinical Trial Logistics
Clinical Trial Logistics
16th to 17th May 2011, Marriott Regents Park, London, United Kingdom.
It currently costs just over £500 million ($800 million) to bring a new chemical to market and development timelines continue to fall in the 10-15 year range. A key reason for high R&D costs is due to logistical failures including failure to recruit patients on time. A way to avoid this is to move clinical trials…
Clinical Trial Logistics
Announcing SMi's 5th annual…
Clinical Trial Logistics conference
16th and 17th May 2011, Central London, UK
www.smi-online.co.uk/2011logistics-london6.asp
It currently costs just over £500 million ($800 million) to bring a new chemical to market and development timelines continue to fall in the 10-15 year range. A key reason for high R&D costs is due to logistical failures including failure to recruit patients on time. A way to avoid this is to move clinical…
